Adenoid cystic carcinoma of the breast is an extremely rare, low-grade malignancy accounting for less than 0.1 percent of all breast diagnoses. Despite exhibiting a triple-negative profile, the tumor displays indolent behavior, a favorable prognosis, and a 10-year survival rate ranging from 85 to 100 percent.
Histological Characteristics and Unique Cell Patterns
Adenoid cystic carcinoma—commonly known as ACC—is a rare form of cancer that typically develops in the salivary glands or other regions of the head and neck. Beyond these primary locations, the malignancy can also occur in the breast, skin, female cervix, male prostate gland, and various other areas. When examined microscopically, ACC tumors reveal a distinctive histological pattern of abnormal nests or cords of epithelial cells that infiltrate ducts or glandular structures within the affected organ. These structures are often filled with a mucous-like material or contain abnormal fibrous membranes.
Medical literature notes that ACC shares a unique dual-cell population of both luminal and basal cells, making it indistinguishable from ACC arising in salivary tissue.
There are three primary histological tumor growth patterns common to ACC: cribriform, tubular, and solid. The cribriform pattern appears as a Swiss cheese pattern in histological stains and, alongside the tubular pattern, tends to be less aggressive. Conversely, tumors exhibiting a solid pattern are more likely to spread, have been associated with activating pathogenic variants or mutations in the NOTCH1 gene, and carry a worse prognosis.
Clinical Presentation in the Breast and Diagnostic Findings
Within the breast, adenoid cystic carcinoma of the breast (ACC) is a rare tumor, comprising <0.1% of all breast cancers. It is more commonly seen in older women, with a mean age at diagnosis of 63, and Caucasian women at greatest risk. Most cases present as a painful, palpable mass located in the outer quadrants of the breast.
Medical documentation highlights a clinical case involving an 88-year-old African American female who presented to an outpatient surgical clinic for a 1-month history of a painful lump in her right breast. The patient had no prior history of mammograms or breast ultrasound, and her family history was unremarkable for breast or ovarian cancer. Physical examination revealed a tender mass palpated in the right breast’s superior lateral peri-areolar region, with no axillary lymphadenopathy present.
Diagnostic imaging via a diagnostic mammogram was performed and found a dense breast with an ill-defined, lobular mass with coarse internal calcifications. Subsequent ultrasound imaging in the 7–8 o’clock axis identified a 1.6 cm by 1 cm heterogeneous, hypoechoic solid mass, alongside a second hypoechoic mass measuring 6 mm by 3 mm located 3 cm from the nipple. The contralateral left breast also showed an irregular solid mass measuring 7 mm by 2.4 mm. The initial mammogram was graded BIRADS 4 for suspicious findings.
Biopsy Confirmation and Dual-Cell Pathology
Definitive diagnosis requires tissue evaluation. Microscopic examination from an ultrasound guided core-needle biopsy from the 7–8 o’clock retro-areolar region shows tumor composed of both luminal and basal cells. These consist of small bland myoepithelial cells with scant cytoplasm and dark compact angular nuclei surrounding pseudoglandular spaces filled with mucin.
Further staining confirms the cellular architecture. The immunohistochemical stain p63 positive for basal cells provides the necessary immunoprofile to support the diagnosis. Following core-needle biopsy, the patient’s condition was upgraded to BIRADS 6 demonstrating known malignancy, with both biopsied regions showing stromal fibrosis and adenosis.
Prognostic Paradox and Metastatic Behavior
One of the most striking anomalies of breast ACC is its behavior relative to its receptor status. Although it is classified as a triple negative tumor; estrogen-, progesterone- and human epidermal growth factor-receptor 2 negative—a classification typically associated with highly aggressive cancers and poor prognoses—ACC maintains an indolent clinical course.
ACC is considered a low-grade malignancy that has a history of slow growth, yet it can be aggressively invasive in other anatomical sites. The tumor is known to infiltrate nearby lymph nodes as well as the sheaths surrounding nerve fibers, a process known as perineural invasion. Recurrence or distant spread can occur months or years after initial treatment, with metastatic disease particularly affecting the lungs in approximately 50% of patients across all primary sites.
Current Treatment Challenges and Management Considerations
Because of the extreme rarity of breast ACC, standardized treatment guidelines remain difficult to establish. Current treatment is focused around surgical resection, however, there are not specific recommendations for the extent of resection due to the lack of cases to draw from.
Unlike conventional breast cancers that frequently spread to the regional drainage basin, ACC rarely metastasizes to the axillary lymph nodes, and therefore dissection is not recommended in the management of this disease. Clinicians must balance surgical management against the indolent yet locally recurrent nature of the tumor, relying heavily on biopsy confirmation and individualized excision strategies.
